Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
SLP 
Simulations Plus Inc (SLP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: SLP (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $23
1 Year Target Price $23
| 5 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -44.52% | Avg. Invested days 19 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 322.44M USD | Price to earnings Ratio - | 1Y Target Price 23 |
Price to earnings Ratio - | 1Y Target Price 23 | ||
Volume (30-day avg) 6 | Beta 1 | 52 Weeks Range 12.39 - 37.67 | Updated Date 10/17/2025 |
52 Weeks Range 12.39 - 37.67 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.15 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-10-22 | When - | Estimate 0.0986 | Actual - |
Profitability
Profit Margin -78.62% | Operating Margin (TTM) 18.15% |
Management Effectiveness
Return on Assets (TTM) 2.74% | Return on Equity (TTM) -41.49% |
Valuation
Trailing PE - | Forward PE 52.91 | Enterprise Value 285245560 | Price to Sales(TTM) 4.01 |
Enterprise Value 285245560 | Price to Sales(TTM) 4.01 | ||
Enterprise Value to Revenue 3.55 | Enterprise Value to EBITDA 20.75 | Shares Outstanding 20127110 | Shares Floating 16638478 |
Shares Outstanding 20127110 | Shares Floating 16638478 | ||
Percent Insiders 17.28 | Percent Institutions 85.49 |
Upturn AI SWOT
Simulations Plus Inc
Company Overview
History and Background
Simulations Plus, Inc. was founded in 1996. The company develops and sells software and consulting services supporting drug discovery, development, and regulatory submissions.
Core Business Areas
- Software: Develops and licenses simulation and modeling software for pharmaceutical and biotechnology companies, academia, and regulatory agencies.
- Consulting: Provides consulting services related to modeling and simulation in drug development.
Leadership and Structure
The leadership team includes Shawn O'Connor (CEO). The company has a board of directors and operates with various departments focused on software development, sales, marketing, and consulting.
Top Products and Market Share
Key Offerings
- GastroPlus: A physiologically-based biopharmaceutics (PBBM) modeling platform used to simulate drug absorption, pharmacokinetics, and pharmacodynamics. Market share for PBPK software estimated to be around 30%. Competitors include Certara, Open Systems Pharmacology, and Schru00f6dinger.
- ADMET Predictor: Software for predicting the absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties of drug candidates. Market share is not available, competitors include Schru00f6dinger, ChemAxon, and Lhasa Limited.
- DDDPlus: Software for mechanistic simulation of IVIVR, dissolution, precipitation and complexation for IVIVC and formulation development. Competitors include Genedata and Instem.
Market Dynamics
Industry Overview
The industry is focused on using modeling and simulation software to improve the efficiency and reduce the costs of drug discovery and development. Regulatory agencies are increasingly encouraging the use of such tools.
Positioning
Simulations Plus is a leader in providing modeling and simulation software and consulting services to the pharmaceutical and biotechnology industries. Their products are used to optimize drug development, improve understanding of drug behavior, and support regulatory submissions.
Total Addressable Market (TAM)
The total addressable market for pharmaceutical modeling and simulation is estimated to be in the hundreds of millions of dollars. Simulations Plus holds a significant position and aims to capture additional market share through product innovation and expanding its customer base.
Upturn SWOT Analysis
Strengths
- Established reputation in the industry
- Strong expertise in modeling and simulation
- Diverse product portfolio
- Strong relationships with regulatory agencies
- Recurring revenue model via software licenses
Weaknesses
- Reliance on the pharmaceutical industry
- Competition from larger companies with more resources
- Potential for disruption from new technologies
- Relatively small market capitalization compared to industry giants
Opportunities
- Expanding into new therapeutic areas
- Developing new software products and services
- Partnering with other companies to broaden its reach
- Leveraging artificial intelligence and machine learning
- Increased regulatory acceptance of modeling and simulation
Threats
- Economic downturn in the pharmaceutical industry
- Increased competition from other software vendors
- Changes in regulatory requirements
- Patent infringement claims
- Cybersecurity threats
Competitors and Market Share
Key Competitors
- Certara (CERT)
- Schru00f6dinger (SDGR)
- Open Systems Pharmacology
Competitive Landscape
Simulations Plus is a leader in the modeling and simulation market, with a strong reputation for its products and services. The company faces competition from larger players, but its deep expertise and focus on the pharmaceutical industry provide a competitive advantage.
Major Acquisitions
Cognigen Corporation
- Year: 2017
- Acquisition Price (USD millions): 37.6
- Strategic Rationale: Expanded Simulations Plus' consulting services and added expertise in pharmacometrics.
DILIsym Services, Inc.
- Year: 2020
- Acquisition Price (USD millions): 23.5
- Strategic Rationale: Expanded Simulations Plus' capabilities in liver safety modeling.
Growth Trajectory and Initiatives
Historical Growth: Historically, Simulations Plus has grown steadily, driven by the increasing adoption of modeling and simulation in the pharmaceutical industry. Revenue growth has been driven by software license renewals, new customer acquisitions, and consulting services.
Future Projections: Future growth projections are positive, based on the expectation that the pharmaceutical industry will continue to invest in modeling and simulation software to improve drug development efficiency. Analyst estimates would be needed to produce accurate projections.
Recent Initiatives: Recent initiatives include expanding its product portfolio through acquisitions (as listed below) and developing new features for existing software products.
Summary
Simulations Plus is a solid company with a strong position in the pharmaceutical modeling and simulation market. Its strengths lie in its established reputation, diverse product portfolio, and recurring revenue model. It needs to be aware of the increased competition from other software vendors and cybersecurity threats.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Simulations Plus, Inc. company website
- Industry reports on pharmaceutical modeling and simulation
- Analyst reports (where available)
- Company Financial Reports
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Market share estimates are approximate and based on available data. Financial metrics are not current.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Simulations Plus Inc
Exchange NASDAQ | Headquaters Research Triangle Park, NC, United States | ||
IPO Launch date 1997-06-18 | CEO - | ||
Sector Healthcare | Industry Health Information Services | Full time employees 243 | Website https://www.simulations-plus.com |
Full time employees 243 | Website https://www.simulations-plus.com | ||
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Research Triangle Park, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.